The Category 2 Ban and the 2026 Reclassification In 2023, the FDA pulled 19 of the most popular peptides BPC-157, TB-500, CJC-1295, among others off the compounding-permitted list and placed them on the restricted Category 2 list, citing safety concerns, impurity issues, and a lack of clinical data
Its important to talk with a healthcare professional about any side effects you may experience
Administered via a subcutaneous injection , Biofusion Glow supports optimal restoration and repair at the cellular level
If it is past the expiry date, replace it rather than using it, since the sterility and preservative strength are only guaranteed up to that date
The timeline varies by injury severity, with acute injuries responding faster than chronic conditions that have been present for months or years